PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: PIPELINE ANALYSIS • Pipeline analysis PART 06: MARKET SIZING Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 07: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 08: MARKET SEGMENTATION BY TYPE OF TREATMENT • Segmentation by type of treatment • Comparison by type of treatment • Drug therapy – Market size and forecast 2017-2022 • Blood transfusion – Market size and forecast 2017-2022 • HSCT – Market size and forecast 2017-2022 • Androgen Therapy – Market size and forecast 2017-2022 • Market opportunity by type of treatment PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • HSCT is the only curative option for myelofibrosis • High off-label prescription including hydroxyurea, Immunomodulators, and steroids PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Bristol-Myers Squibb • CELGENE • Incyte • Novartis PART 16: APPENDIX • List of abbreviations     Exhibit 01: Global oncology therapeutics market Exhibit 02: Global oncology therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Pipeline molecules for myelofibrosis 2017-2018 Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2017 Exhibit 08: Validation techniques employed for market sizing 2017 Exhibit 09: Global – Market size and forecast 2017-2022 ($ mn) Exhibit 10: Global – Year-over-year growth 2018-2022 (%) Exhibit 11: Five forces analysis 2017 Exhibit 12: Five forces analysis 2022 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2017 Exhibit 19: Type of treatment – Market share 2017-2022 (%) Exhibit 20: Comparison by type of treatment Exhibit 21: Drug therapy – Market size and forecast 2017-2022 ($ mn) Exhibit 22: JAKAVI/JAKAFI sales from 2015-2017 Exhibit 23: Drug therapy – Year-over-year growth 2018-2022 (%) Exhibit 24:  Blood transfusion – Market size and forecast 2017-2022 ($ mn) Exhibit 25: Blood transfusion – Year-over-year growth 2018-2022 (%) Exhibit 26: HSCT – Market size and forecast 2017-2022 ($ mn) Exhibit 27: HSCT – Year-over-year growth 2018-2022 (%) Exhibit 28: Androgen therapy – Market size and forecast 2017-2022 ($ mn) Exhibit 29: Androgen Therapy – Year-over-year growth 2018-2022 (%) Exhibit 30: Market opportunity by type of treatment Exhibit 31: Customer landscape Exhibit 32: Global – Market share by geography 2017-2022 (%) Exhibit 33: Regional comparison Exhibit 34: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 35: Americas – Year-over-year growth 2018-2022 (%) Exhibit 36: Top 3 countries in Americas Exhibit 37: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 38: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 39: Top 3 countries in EMEA Exhibit 40: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 41: APAC – Year-over-year growth 2018-2022 (%) Exhibit 42: Top 3 countries in APAC Exhibit 43: Market opportunity Exhibit 44: Vendor landscape Exhibit 45: Landscape disruption Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: Bristol-Myers Squibb – Overview Exhibit 49: Bristol-Myers Squibb – Business segments Exhibit 50: Bristol-Myers Squibb – Organizational developments Exhibit 51: Bristol-Myers Squibb – Geographic focus Exhibit 52: Bristol-Myers Squibb – Key offerings Exhibit 53: Bristol-Myers Squibb – Key customers Exhibit 54: CELGENE – Overview Exhibit 55: CELGENE – Business segments Exhibit 56: CELGENE – Organizational developments Exhibit 57: CELGENE – Geographic focus Exhibit 58: CELGENE – Key offerings Exhibit 59: CELGENE – Key customers Exhibit 60: Incyte – Overview Exhibit 61: Incyte – Business segments Exhibit 62: Incyte – Organizational developments Exhibit 63: Incyte – Geographic focus Exhibit 64: Incyte – Key offerings Exhibit 65: Incyte – Key customers Exhibit 66: Novartis – Overview Exhibit 67: Novartis – Business segments Exhibit 68: Novartis – Organizational developments Exhibit 69: Novartis – Geographic focus Exhibit 70: Novartis – Segment focus Exhibit 71: Novartis – Key offerings Exhibit 72: Novartis – Key customers    

Bristol-Myers Squibb CELGENE Incyte Novartis